$5.325
-0.112 (-2.11%)收盤時
CING 資訊
CING 事件
Cingulate Publishes CTx-1301 Bioavailability Study
Cingulate announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs. The manuscript provides clinicians and researchers with pharmacokinetic data supporting CTx-1301, Cingulate's lead product candidate for the treatment of ADHD. The publication reports that CTx-1301 achieved plasma dexmethylphenidate concentrations comparable to the reference product during the early portion of the dosing interval while maintaining higher plasma concentrations later in the day, consistent with the product's proprietary trimodal release profile. In the study, CTx-1301 also demonstrated fewer treatment-emergent adverse events than the reference bimodal formulation, despite delivering a higher overall dexmethylphenidate dose.
Cingulate Secures ADHD Treatment Patent Until 2042
Cingulate announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301, for the treatment of Attention Deficit Hyperactivity Disorder, or ADHD. The patent, issued by the United States Patent and Trademark Office, or USPT, on June 16, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301's formulation and method of use through December 2042.
Eagle Nuclear Energy Borrow Rate Increases to 115.96%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Aureus Greenway Holdings Inc (PUSA) 64.84% +2.73, Tradr 2X Short SNDK Daily ETF (SNDQ) 29.81% +1.60, Lucid Group (LCID) 10.55% +1.58, Defiance 1.75x MSTR ETF (MSTX) 18.61% +0.85, Eagle Nuclear Energy Corp (NUCL) 115.96% +0.44, Applix Inc. (APLX) 14.48% +0.35, Cingulate Inc (CING) 12.67% +0.33, Lam Research (LRCX) 0.54% +0.29, iShares DJ US Real Estate Index Fund (IYR) 1.08% +0.24, and American Bitcoin Corp (ABTC) 0.92% +0.23.
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Cingulate announced that the FDA has issued a complete response letter for its new drug application for CTx-1301 for the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. The response identified specific Chemistry, Manufacturing and Controls information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. Cingulate expects a prompt submission to FDA of the requested information addressing issues raised. "We are encouraged that the FDA's response was limited to specific information requests related to CMC and did not currently identify any issues related to the clinical safety or efficacy of CTx-1301," said Cingulate CEO Shane Schaffer. "Our immediate priority is to complete the CMC work already underway with our manufacturing partner; we believe the outstanding requests will be addressed quickly as we move efficiently toward resubmission. Importantly, we have nearly $30 million in cash reserves, which we believe provides sufficient capital to address the issues raised and execute on the resubmission process and continue pre-commercial activities into 2027."
Cingulate Files to Sell 4.21M Shares of Common Stock
Cingulate files to sell 4.21M shares of common stock for holders
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。